Advertisement

Acta Neurochirurgica

, Volume 153, Issue 1, pp 181–190 | Cite as

Evaluation of efficacy and safety of fentanyl transdermal patch (Durogesic®D-TRANS) in chronic pain

  • Jin Hoon Park
  • Jeoung Hee Kim
  • Sung Cheol Yun
  • Sung Woo Roh
  • Seung Chul Rhim
  • Chang Jin Kim
  • Sang Ryong JeonEmail author
Clinical Article

Abstract

Purpose

Opioids are used in controlling several types of pain. This study was designed to evaluate the efficacy and safety of the fentanyl transdermal patch-type system (Durogesic® D-TRANS).

Methods

Patients who complained of chronic moderate to severe pain were enrolled. Administration dosages of fentanyl patch started from 12.5 μg/h and could be increased by 12.5 μg/h or 25 μg/h, if the average pain score of 4 or higher occurred within 72 h. The total administration period was 12 weeks. The type, location, characteristics, and duration of pain were evaluated. Also, on day 0, weeks of 4, 8, and 12, the physician’s assessment of pain intensity, the patient’s assessment of pain intensity, the assessment of impact of pain on functions, and the assessment of the impact of pain on sleep were assessed. In addition, side effects were evaluated during the study duration.

Results

A total of 65 cases were enrolled, and the final evaluated cases were 41. Before treatment, the average physician’s assessment of pain intensity was 6.70 ± 1.41, and the average patient’s assessment of pain intensity was 7.02 ± 1.63. In the final visit, the average physician’s assessment of pain intensity was 2.58 ± 1.72, and the average patient’s assessment of pain intensity was 2.86 ± 1.78.

Conclusions

This prospective study shows that the fentanyl patch is effective in alleviating moderate to severe chronic noncancer pain including neuropathic pain down to mild pain. Therefore, the fentanyl patch should be considered before other invasive intervention procedures in chronic moderate to severe noncancer pain.

Keywords

Fentanyl patch Chronic pain Neuropathic pain Nociceptive pain 

Notes

Acknowledgements

The authors express their gratitude to Sun Keun Huh for his assistance in the collection of data. This research was financially supported by a grant (protocol number FEN-KOR-10) from Janssen Korea, Seoul, South Korea, whose role was restricted to providing assistance to the investigators in the conception, conduct, and analysis of this study.

Conflicts of interest

None

References

  1. 1.
    Agarwal S, Polydefkis M, Block B, Haythornthwaite J, Raja SN (2007) Transdermal fentanyl reduces pain and improves functional activity in neuropathic pain states. Pain Med 8:554–562CrossRefPubMedGoogle Scholar
  2. 2.
    Ahmedzai S, Brooks D (1997) Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-fentanyl comparative trial group. J Pain Symptom Manag 13:254–261CrossRefGoogle Scholar
  3. 3.
    Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, Kalso E (2001) Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 322:1154–1158CrossRefPubMedGoogle Scholar
  4. 4.
    Anon (1997) The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. Pain Forum 77–79Google Scholar
  5. 5.
    Arner S, Meyerson BA (1988) Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 33:11–23CrossRefPubMedGoogle Scholar
  6. 6.
    Asbury AK, Fields HL (1984) Pain due to peripheral nerve damage: an hypothesis. Neurology 34:1587–1590PubMedGoogle Scholar
  7. 7.
    Bolay H, Moskowitz MA (2002) Mechanisms of pain modulation in chronic syndromes. Neurology 59(Suppl 2):S2–S7Google Scholar
  8. 8.
    Brown RL, Fleming MF, Patterson JJ (1996) Chronic opioid analgesic therapy for chronic low back pain. J Am Board Fam Pract 9:191–204PubMedGoogle Scholar
  9. 9.
    Cummings-Ajemian I (1993) Treatment of related symptoms. In: Patt RB (ed) Cancer pain: Section III. Non-pharmacological treatment and novel approaches to management. JB Lippincott, PhiladelphiaGoogle Scholar
  10. 10.
    Dellemijn PL, Vanneste JA (1997) Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 349:753–758CrossRefPubMedGoogle Scholar
  11. 11.
    Donner B, Zenz M, Strumpf M, Raber M (1998) Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 15:168–175CrossRefPubMedGoogle Scholar
  12. 12.
    Donner B, Zenz M, Tryba M, Strumpf M (1996) Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 64:527–534CrossRefPubMedGoogle Scholar
  13. 13.
    Graziotti PJ, Goucke CR (1997) The use of oral opioids in patients with chronic non-cancer pain. Management strategies. Med J Aust 167:30–34PubMedGoogle Scholar
  14. 14.
    Grond S, Zech D, Lehmann KA, Radbruch L, Breitenbach H, Hertel D (1997) Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 69:191–198CrossRefPubMedGoogle Scholar
  15. 15.
    Jadad AR, Carroll D, Glynn CJ, Moore RA, McQuay HJ (1992) Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet 339:1367–1371CrossRefPubMedGoogle Scholar
  16. 16.
    Jumbelic MI (2010) Deaths with transdermal fentanyl patches. Am J Forensic Med Pathol 31:1–4CrossRefGoogle Scholar
  17. 17.
    Koltzenburg M, Torebjörk HE, Wahren LK (1994) Nociceptor modulated central sensitization causes mechanical hyperalgesia in acute chemogenic and chronic neuropathic pain. Brain 117:579–591CrossRefPubMedGoogle Scholar
  18. 18.
    Kosinski MR, Schein JR, Vallow SM, Ascher S, Harte C, Shikiar R, Frank L, Margolis MK, Vorsanger G (2005) An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system. Curr Med Res Opin 21:849–862CrossRefPubMedGoogle Scholar
  19. 19.
    Kupers RC, Konings H, Adriaensen H, Gybels JM (1991) Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. Pain 47:5–12CrossRefPubMedGoogle Scholar
  20. 20.
    Max MB, Schafer SC, Culnane M, Dubner R, Gracely RH (1988) Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther 43:363–371CrossRefPubMedGoogle Scholar
  21. 21.
    McQuay H (1999) Opioids in pain management. Lancet 353:2229–2232CrossRefPubMedGoogle Scholar
  22. 22.
    Melzack R (1990) The tragedy of needless pain. Sci Am 262:27–33CrossRefPubMedGoogle Scholar
  23. 23.
    Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H (1996) Randomised trial of oral morphine for chronic non-cancer pain. Lancet 347:143–147CrossRefPubMedGoogle Scholar
  24. 24.
    Mystakidou K, Befon S, Tsilika E, Dardoufas K, Georgaki S, Vlahos L (2002) Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids. Oncology 62:9–16CrossRefPubMedGoogle Scholar
  25. 25.
    Mystakidou K, Parpa E, Tsilika E, Mavromati A, Smyrniotis V, Georgaki S, Vlahos L (2003) Long-term management of noncancer pain with transdermal therapeutic system—fentanyl. J Pain 4:298–306CrossRefPubMedGoogle Scholar
  26. 26.
    Ozaki S, Narita M, Iino M, Miyoshi K, Suzuki T (2003) Suppression of the morphine-induced rewarding effect and G-protein activation in the lower midbrain following nerve injury in the mouse: involvement of G-protein-coupled receptor kinase 2. Neuroscience 116:89–97CrossRefPubMedGoogle Scholar
  27. 27.
    Ozaki S, Narita M, Ozaki M, Khotib J, Suzuki T (2004) Role of extracellular signal-regulated kinase in the ventral tegmental area in the suppression of the morphine-induced rewarding effect in mice with sciatic nerve ligation. J Neurochem 88:1389–1397CrossRefPubMedGoogle Scholar
  28. 28.
    Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R (1998) Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 16:1588–1593PubMedGoogle Scholar
  29. 29.
    Portenoy RK (1990) Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 5:S46–S62CrossRefPubMedGoogle Scholar
  30. 30.
    Porter J, Jick H (1980) Addiction rare in patients treated with narcotics. N Engl J Med 302:123PubMedGoogle Scholar
  31. 31.
    Rowbotham MC, Reisner-Keller LA, Fields HL (1991) Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 41:1024–1028PubMedGoogle Scholar
  32. 32.
    Schug SA, Merry AF, Acland RH (1991) Treatment principles for the use of opioids in pain of nonmalignant origin. Drugs 42:228–239CrossRefPubMedGoogle Scholar
  33. 33.
    Suzuki T, Kishimoto Y, Misawa M, Nagase H, Takeda F (1999) Role of the kappa-opioid system in the attenuation of the morphine-induced place preference under chronic pain. Life Sci 64:PL1–7Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Jin Hoon Park
    • 1
  • Jeoung Hee Kim
    • 1
  • Sung Cheol Yun
    • 2
  • Sung Woo Roh
    • 1
  • Seung Chul Rhim
    • 1
  • Chang Jin Kim
    • 1
  • Sang Ryong Jeon
    • 1
    Email author
  1. 1.Department of Neurological Surgery, College of Medicine ASAN Medical CenterUniversity of UlsanSeoulSouth Korea
  2. 2.Department of Preventive Medicine, College of Medicine, ASAN Medical CenterUniversity of UlsanSeoulSouth Korea

Personalised recommendations